Navigation Links
With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
Date:12/13/2010

EXTON, Pa., Dec. 13, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. finds that with the introduction of Novartis' Gilenya, the first oral disease-modifying agent (DMA) for the treatment of multiple sclerosis (MS), neurologists anticipate major shifts in the landscape of the MS market. One month after the launch of Gilenya, trial and uptake of Extavia, a DMA launched by Novartis one year earlier, continues to be tempered due to the perception that Extavia is a "me too" agent -a perception made even more noticeable by the availability of the new and unique DMA, Gilenya. In fact, compared to previous waves, both current and anticipated patient share of Extavia have decreased due in part to a drop in the number of high prescribers of Extavia.

The recently released fourth and final wave of the LaunchTrends®: Extavia report series finds that the small amount of Extavia use is mostly driven by out-of-pocket cost concerns with other DMAs and that managed care reimbursement is playing less of a role compared to the role it played in the first year of Extavia's commercial availability. In fact, perceptions of the managed care process for Extavia have declined since earlier waves. While Novartis detailing seems to be primarily focused on Gilenya, neurologists who were recently detailed on Extavia are more likely to have experience with the DMA. While anticipated prescribing of Gilenya is expected to rise substantially over the next six months, surveyed neurologists believe that any change in their prescribing of Extavia will be minimal.

LaunchTrends®: Extavia is a four wave syndicated report series designed to track the uptake of Novartis's Extavia at one month, six months, nine months and one year following its commercial availability. In the current wave of research which measures Extavia's market impact after one year, BioTrends surveyed 76 neurologists and conducted qualitative interviews with a subset of
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
2. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix
3. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: IMMU, KYUS
4. [video] Wall St. Networks 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: GTHR, BHRT, AGO
5. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
6. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
7. New Report Provides Expert Analysis of Recent Advances and Setbacks in Parkinsons Disease Drug Development
8. Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
9. American Oriental Bioengineering Comments on Recent Property Purchase
10. Recent Advances in Organic Chemistry Using Real-Time In Situ FTIR
11. Recent Reports Regarding Mercury and High Fructose Corn Syrup Flawed and Misleading
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Northwest Biotherapeutics (NASDAQ: NWBO ) ... personalized immune therapies for solid tumor cancers, announced today ... American Society Of Clinical Oncology (ASCO) meeting in ... in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... pre-eminent conference focused on clinical treatment of cancer, with ...
(Date:5/23/2013)...  Verenium Corporation (Nasdaq: VRNM ), a ... commercialization of high-performance enzymes, today announced that ... at two upcoming conferences. (Logo: http://photos.prnewswire.com/prnh/20120924/MM79973LOGO ... Second Annual Marcum LLP Microcap Conference on Thursday, May ... York City.  The presentation is scheduled to begin at ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 SynCardia Systems, ... and only FDA, Health Canada and CE (Europe) approved ... Centre in Scotland, which boasts more than 380,000 visitors ... Heart powered by the Freedom® portable driver as ... the most advanced exhibitions of its kind. , ...
(Date:5/23/2013)... Philadelphia, PA (PRWEB) May 23, 2013 ... said that the university had already confirmed it. Meanwhile, My ... to help bed bug victims fight the pests without using ... was posted on May 15, 2013, the affected building was ... about it being infested was said made on May 13 ...
Breaking Biology Technology:NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2
... SOUTH SAN FRANCISCO, Calif., Nov. 1, 2010 diaDexus, ... diagnostics company focused on the development and commercialization of ... needs in cardiovascular disease, today announced that the company, ... OTC Bulletin Board under the ticker symbol (VXGN), has ...
... AMGN ) Senior Vice President of Research and ... U.S. Food and Drug Administration (FDA) panel charged with implementing ... patient safety and follow a science-based approach. "Put ... "Amgen believes biosimilars have a meaningful role to play in ...
... ... ... var shortURL = ... need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var ...
Cached Biology Technology:diaDexus Announces Name Change From VaxGen 2diaDexus Announces Name Change From VaxGen 3Amgen to Provide Testimony at FDA Hearing on Biosimilars 2Amgen to Provide Testimony at FDA Hearing on Biosimilars 3Amgen to Provide Testimony at FDA Hearing on Biosimilars 4NEURO-BIOTECH CORPORATION: Updates and latest developments 2NEURO-BIOTECH CORPORATION: Updates and latest developments 3NEURO-BIOTECH CORPORATION: Updates and latest developments 4NEURO-BIOTECH CORPORATION: Updates and latest developments 5NEURO-BIOTECH CORPORATION: Updates and latest developments 6NEURO-BIOTECH CORPORATION: Updates and latest developments 7NEURO-BIOTECH CORPORATION: Updates and latest developments 8NEURO-BIOTECH CORPORATION: Updates and latest developments 9
(Date:5/22/2013)... technique that can detect molecular variants in chemical mixtures ... the most important, though time-consuming, processes in analytical chemistry. ... Nature , post-doctoral researcher David Patterson, Professor of Physics ... for Free-Electron Laser Science (CFEL) in Hamburg, Germany developed ... identify molecular variants apart, and to determine how much ...
(Date:5/22/2013)... and human health effects from disposal of millions ... scientists to recommend stronger government policies to encourage ... materials. That,s the conclusion of a new paper ... Technology . , Oladele A. Ogunseitan and colleagues ... for powering everything from smart phones to components ...
(Date:5/22/2013)... Early screening for prostate cancer could become as easy ... thanks to UC Irvine research published today in the ... After more than a decade of work, UC Irvine ... usable markers for prostate cancer in urine, meaning that ... accuracy and at dramatically lower cost. The same technology ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3UCI chemists devise inexpensive, accurate way to detect prostate cancer 2UCI chemists devise inexpensive, accurate way to detect prostate cancer 3
... This release is available in Spanish . ... diseases found in South America that can cause terrible, ... effective. Now, Howard Hughes Medical Institute (HHMI) ... World hemorrhagic fever virus latches onto and infects human ...
... and the food industry are collaborating to discover how taste ... will work together to hone the make-up of a perfect ... John Innes Centre, the project partners will find new ways ... food market. They will also study the likely impact of ...
... with Ritalin every year to improve their ability to ... also directly enhances the speed of learning. ... time that Ritalin boosts both of these cognitive abilities ... inside the brain. Neurotransmitters are the chemical messengers neurons ...
Cached Biology News:New ways to disarm deadly South American hemorrhagic fever viruses 2New ways to disarm deadly South American hemorrhagic fever viruses 3Perfect peas to push profits and cut carbon 2Ritalin boosts learning by increasing brain plasticity 2
... Sub-Plates are E.Coli glycerol stocks contained in ... 50 cDNA clones with approximately 5,000 clones ... a master plate well, the corresponding subplate ... to identify the positive well(s). Cells from ...
... for analytical performance , ... the ultimate in analytical,performance, the ... 810-MS features include: , ... providing reliable, routine, trace level,quantification. ...
... designed for flexibility and routine operation. With ... lens, true hyperbolic quadrupole and high-speed simultaneous ... range of sample types and applications. New ... standard Agilents unique ShieldTorch System, which enables ...
... Identical to the DH-2000, except that it ... 190-1700 nm wavelength range and comes with a ... up to 5 Hz) The DH-2000 ... spectrum of deuterium and tungsten halogen light sources ...
Biology Products: